Understanding the concept of early scientific advice and its purpose across HTA markets

Uncertainty and inappropriate trial design are the main reasons why medicines fare badly in health technology assessments (HTA). HTA scientific advice recommendations can identify key payer evidence requirements and areas of uncertainty, and when implemented result in stronger HTA submissions. 

These slides are from our on-demand webinar “Understanding the concept of early scientific advice and its purpose across HTA markets” where market access experts discuss:

  • Why industry is increasingly utilizing HTA scientific advice as part of early development planning. 
  • Examine the considerations for and feasibility of obtaining HTA scientific advice across key markets. 
  • Explore the HTA challenges that contribute to the prioritization of candidate assets for HTA scientific advice and the framing of key questions. 

FREE Slides

Fill in your details to download your FREE Slides

We respect your privacy. Cookie policy.

Latest insights

Driving BioPharma Access in Europe: Insights for ...

PRMA Consulting becomes Avalere Health, creating the ...

World Orphan Drug Congress 2023: solutions for market ...